Introduction
Pseudoprogression (psPD) is now recognized following radiotherapy with concurrent temozolomide (RT/TMZ) for glioblastoma multiforme (GBM). The purpose of this study was to explore biomarker expression profile of GBM patients with psPD.
Publications
Molecular Profiling of GBM Patients Developed Pseudoprogression After Chemoradiation Treatment
– Caris Life Sciences
Download Publication